Bio-Rad expands droplet digital PCR portfolio with four new platforms
Bio-Rad Laboratories has significantly bolstered its digital PCR capabilities through the launch of four new Droplet Digital™ PCR (ddPCR™) platforms, combining internal development with strategic acquisition assets from Stilla Technologies. The expansion positions the California-based company at the forefront of absolute quantification technologies for clinical and research applications.
Strategic acquisition drives portfolio expansion
The newly introduced instruments comprise Bio-Rad’s proprietary QX Continuum™ ddPCR system alongside three QX700™ series platforms acquired through the recent Stilla Technologies acquisition. Together with existing QX200™ and QX600™ systems, the comprehensive portfolio now encompasses over 400,000 assays, establishing what the company describes as the market’s most extensive digital PCR offering.“With this launch, our expanded portfolio of instruments, reagents, software, and services extends Bio-Rad’s presence in the genomics research and applied science markets and strengthens our leadership in droplet digital PCR solutions,” said Jim Barry, EVP and President of Bio-Rad’s Life Science Group.
Advanced multiplexing capabilities target diverse applications
The QX Continuum ddPCR system addresses translational research requirements through qPCR-like workflow simplicity, featuring four-colour multiplexing and up to eight discrete thermal profiles per plate in an integrated configuration. This design targets applications spanning oncology, infectious disease, and genetic research with enhanced workflow efficiency.
The QX700 series delivers expanded capabilities for academic research, environmental testing, cell and gene therapy, and biopharmaceutical quality control. These instruments enable seven-colour multiplexing with capacity exceeding 700 samples per day, incorporating minimal input volume requirements and continuous loading functionality.
Market positioning and clinical implications
Barry emphasised the strategic significance: “The newly introduced platforms complement Bio-Rad’s existing QX ddPCR portfolio and offer our customers unparalleled workflow simplicity and throughput capabilities across the full spectrum of digital PCR applications including oncology, infectious disease, and genetic research.”
For more information, visit: https://www.bio-rad.com/dropletdigitalPCR
Digital issue: Please click here for more information
